Drugs & Targets Merck will withdraw Keytruda’s “dangling” indication for gastric cancer July 09, 2021Vol.47 No.27
Drugs & Targets Rylaze receives FDA approval as component of chemotherapy regimen for leukemia and lymphoma July 02, 2021Vol.47 No.26
Drugs & Targets EC approves Opdivo + Yervoy for adults in dMMR or MSI-H metastatic colorectal cancer indication July 02, 2021Vol.47 No.26
Drugs & Targets EC approves Keytruda + chemo for esophageal cancer or HER2-negative gastroesophageal junction adenocarcinoma July 02, 2021Vol.47 No.26
Drugs & Targets EC approves Libtayo for first-line treatment of advanced NSCLC with ≥50% PD-L1 expression July 02, 2021Vol.47 No.26
Drugs & TargetsFree Libtayo approved by European Commission for first-line treatment of patients with advanced NSCLC with ≥50% PD-L1 expression June 25, 2021Vol.47 No.25
Drugs & TargetsFree Abecma receives positive CHMP opinion for relapsed and refractory multiple myeloma June 25, 2021Vol.47 No.25
Drugs & TargetsFree Opdivo receives positive CHMP opinion as adjuvant treatment for GEJ cancer patients with residual pathologic disease following chemoradiotherapy June 25, 2021Vol.47 No.25
Drugs & TargetsFree European Commission approves Onureg for certain AML subtypes June 25, 2021Vol.47 No.25
